INmune Bio Highlights CORDStrom RDEB Program and IP Strength

The latest update is out from Inmune Bio ( (INMB) ).

INmune Bio has released a new corporate slide presentation dated March 2025 outlining its late-stage pipeline in inflammation and immunology, with an emphasis on CORDStrom as a systemic therapy for the ultra-rare skin disorder RDEB and XPro1595 for neurologic indications. The materials highlight favorable patent and exclusivity positions through at least 2045, underscoring long-duration intellectual property protection that could enhance the commercial value of its lead assets and strengthen the company’s strategic position in rare disease and neuroinflammation markets.

The presentation also frames CORDStrom as a de-risked, scalable asset in RDEB, aligning its Phase III trial design with evolving U.S. regulatory thinking that recognizes itch and pain reduction as key clinical endpoints instead of solely wound surface area. By focusing on the “itch-pain” cycle, mental health and systemic disease burden in RDEB, INmune Bio positions its program to meet patient-prioritized needs and potentially secure a differentiated foothold in a high-unmet-need niche, which could be meaningful for patients, clinicians and future commercial partners if clinical and regulatory milestones are met.

The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Score is held back primarily by weak financial performance (large losses and sustained cash burn). The latest earnings call provides a meaningful offset via improved quarterly loss profile, stated cash runway into late 2026, and defined regulatory milestones, while technicals are mixed and valuation is constrained by negative earnings and no dividend.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a biotechnology company focused on modulating the innate immune system to treat inflammation-driven diseases. Its pipeline includes candidates such as CORDStrom and XPro1595, which target systemic inflammatory pathways and are being developed for conditions including neurologic diseases and ultra-rare disorders like recessive dystrophic epidermolysis bullosa (RDEB), with patent coverage extending into the 2040s.

Average Trading Volume: 420,328

Technical Sentiment Signal: Sell

Current Market Cap: $35.62M

For an in-depth examination of INMB stock, go to TipRanks’ Overview page.